BIS ETF Research - UltraShort Nasdaq Biotechnology

UltraShort Nasdaq Biotechnology (bis)

Last Updated by Anonymous | Update This Page Now

►Summary | Add New ETF | Feedback

Short Term Rating Stock Ratings Help
placeholder_summary.png

Asset Allocation (% of Port)

US Stocks
Non-US Stocks
Bonds
Cash
Other
%
%
%
%
%

Geographic Allocation (% of Port)

North America
Europe
Asia
South America
Africa
Australia + Pacific Islands
Long Term Rating Stock Ratings Help

SELL

SWOT Statistics

Strengths + Opportunities = 59

Threats + Weaknesses = 37

When strengths & opportunities substantially exceed threats & weaknesses an investment in the bis ETF has great long term potential.

ETF Description Update

UltraShort Nasdaq Biotechnology (BIS) Description: BIS is an exchange trading fund (ETF), which is a security that tracks a basket of assets, but trades like a stock. BIS exchange trading fund (ETF) tracks the Biotechnology (-200%); this equity index contains nsdq listed companies classified as either biotechnology or pharmaceuticals companies. UltraShort Nasdaq Biotechnology (BIS) falls under the Leveraged Equities category. BIS's dividend yield is roughly 0%, it has an expense ratio of 0.95%, and is in the equity ETF asset class. UltraShort Nasdaq Biotechnology (BIS) focuses its investments in the U.S. region of the world. BIS has an ETF leverage of two times (2x) and the performance of the BIS ETF is inversely-related to its benchmark; in other words, BIS is short the index. The BIS ETF belongs to the Health & Biotech sector. An investor can find BIS's top holdings, fundamental analysis, and fund ratings on the left side of the screen. The right side features BIS's technical analysis chart and long term fund potential. Long term and short term buy ratings indicate our highest possible valuation rating. Click here for additional information on ProShares ETF funds or see the ETF research & analysis home page to start.

Portfolio Strategy Update

Be the first to explain UltraShort Nasdaq Biotechnology (BIS)'s strategy.


Performance Analysis Update